Retrospective cohort study evaluates GLP-1 receptor agonist therapy effects on migraine frequency and disability, suggesting variable outcomes.
This study evaluated whether glucagon-like peptide-1 (GLP-1) receptor agonist therapy reduces migraine frequency and disability.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: